Biotech | April 29, 2022
Moderna files for authorization of its Covid-19 vaccine in young children six months to six years
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
Covaxin was earlier approved for children 12-18 years of age
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
The peptide-based vaccine induces a t cell-dependent response
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Subscribe To Our Newsletter & Stay Updated
